バイオ医薬品の世界市場：洞察、競合情勢、市場予測：2030年

世界のバイオ医薬品の市場規模は、2024年から2030年までの予測期間中に7.98%のCAGRで拡大し、2030年には7,136億1,000万米ドルに達すると予測されています。バイオ医薬品の需要は、主に慢性疾患、感染症、神経疾患の負担増と世界の高齢者人口の増加が後押ししています。さらに、バイオ医薬品や個別化医薬品の受け入れ拡大、以前は治療不可能であった疾患を治療するバイオ医薬品の能力、研究開発の熟練度に対する支出の増加、ヘルスケア施設の状態改善に対する注目の高まり、全体的なヘルスケアインフラの改善、製品の上市と承認の増加、製品開発における技術革新などが、2024年～2030年の予測期間におけるバイオ医薬品市場全体の成長に寄与しています。

世界中でがん、神経疾患などの慢性疾患の有病率が増加しており、バイオ医薬品の市場全体が拡大すると考えられます。例えば、Globocan Statistics 2020によると、2020年には世界中で約1,930万人ががんに罹患し、1,000万人以上ががんで死亡しています。

当レポートでは、世界のバイオ医薬品市場について調査し、市場の概要とともに、製品タイプ別、用途別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 バイオ医薬品市場レポートのイントロダクション

第2章 バイオ医薬品市場のエグゼクティブサマリー

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 バイオ医薬品市場の主な要因分析

• バイオ医薬品市場の促進要因
• バイオ医薬品市場の抑制要因と課題
• バイオ医薬品市場の機会

第5章 バイオ医薬品市場におけるポーターのファイブフォース分析

第6章 バイオ医薬品市場の概要

• 製品タイプ別
• 用途別
• 地域別

第7章 バイオ医薬品市場の企業と製品プロファイル

• AbbVie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Johnson & Johnson
• Novartis AG
• Novo Nordisk AS
• Pfizer Inc.
• GSK plc.
• F. Hoffmann-La Roche Ltd
• Merck KGaA
• Sanofi SA
• AstraZeneca PLC
• Bayer AG
• Takeda Pharmaceutical Company Limited.
• UCB S.A.
• Boehringer Ingelheim International GmbH
• DAIICHI SANKYO COMPANY, LIMITED
• Biogen
• Serum Institute of India

第8章 KOL の見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightのサービス内容

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Biopharmaceuticals Market in Global (2021-2030)
• Table 3: Biopharmaceuticals Market in Global by Product Type (2021-2030)
• Table 4: Biopharmaceuticals Market in Global by Application (2021-2030)
• Table 5: Biopharmaceuticals Market in Global by Geography (2021-2030)
• Table 6: Biopharmaceuticals Market in North America (2021-2030)
• Table 7: Biopharmaceuticals Market in the US (2021-2030)
• Table 8: Biopharmaceuticals Market in Canada (2021-2030)
• Table 9: Biopharmaceuticals Market in Mexico (2021-2030)
• Table 10: Biopharmaceuticals Market in Europe (2021-2030)
• Table 11: Biopharmaceuticals Market in France (2021-2030)
• Table 12: Biopharmaceuticals Market in Germany (2021-2030)
• Table 13: Biopharmaceuticals Market in the United Kingdom (2021-2030)
• Table 14: Biopharmaceuticals Market in Italy (2021-2030)
• Table 15: Biopharmaceuticals Market in Spain (2021-2030)
• Table 16: Biopharmaceuticals Market in the Rest of Europe (2021-2030)
• Table 17: Biopharmaceuticals Market in Asia-Pacific (2021-2030)
• Table 18: Biopharmaceuticals Market in China (2021-2030)
• Table 19: Biopharmaceuticals Market in Japan (2021-2030)
• Table 20: Biopharmaceuticals Market in India (2021-2030)
• Table 21: Biopharmaceuticals Market in Australia (2021-2030)
• Table 22: Biopharmaceuticals Market in South Korea (2021-2030)
• Table 23: Biopharmaceuticals Market in Rest of Asia-Pacific (2021-2030)
• Table 24: Biopharmaceuticals Market in the Rest of the World (2021-2030)
• Table 25: Biopharmaceuticals Market in the Middle East (2021-2030)
• Table 26: Biopharmaceuticals Market in Africa (2021-2030)
• Table 27: Biopharmaceuticals Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Biopharmaceuticals Market in Global (2021-2030)
• Figure 3: Biopharmaceuticals Market in Global by Product Type (2021-2030)
• Figure 4: Biopharmaceuticals Market in Global by Application (2021-2030)
• Figure 5: Biopharmaceuticals Market in Global by Geography (2021-2030)
• Figure 6: Biopharmaceuticals Market in North America (2021-2030)
• Figure 7: Biopharmaceuticals Market in the US (2021-2030)
• Figure 8: Biopharmaceuticals Market in Canada (2021-2030)
• Figure 9: Biopharmaceuticals Market in Mexico (2021-2030)
• Figure 10: Biopharmaceuticals Market in Europe (2021-2030)
• Figure 11: Biopharmaceuticals Market in France (2021-2030)
• Figure 12: Biopharmaceuticals Market in Germany (2021-2030)
• Figure 13: Biopharmaceuticals Market in the United Kingdom (2021-2030)
• Figure 14: Biopharmaceuticals Market in Italy (2021-2030)
• Figure 15: Biopharmaceuticals Market in Spain (2021-2030)
• Figure 16: Biopharmaceuticals Market in the Rest of Europe (2021-2030)
• Figure 17: Biopharmaceuticals Market in Asia-Pacific (2021-2030)
• Figure 18: Biopharmaceuticals Market in China (2021-2030)
• Figure 19: Biopharmaceuticals Market in Japan (2021-2030)
• Figure 20: Biopharmaceuticals Market in India (2021-2030)
• Figure 21: Biopharmaceuticals Market in Australia (2021-2030)
• Figure 22: Biopharmaceuticals Market in South Korea (2021-2030)
• Figure 23: Biopharmaceuticals Market in Rest of Asia-Pacific (2021-2030)
• Figure 24: Biopharmaceuticals Market in the Rest of the World (2021-2030)
• Figure 25: Biopharmaceuticals Market in the Middle East (2021-2030)
• Figure 26: Biopharmaceuticals Market in Africa (2021-2030)
• Figure 27: Biopharmaceuticals Market in South America (2021-2030)
• Figure 28: Market Drivers
• Figure 29: Market Barriers
• Figure 30: Marker Opportunities
• Figure 31: PORTER'S Five Force Analysis

Biopharmaceuticals Market By Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Protein, Recombinant Protein, Recombinant Hormones, Synthetic Immunomodulators, And Others), Application (Oncology, Inflammatory And Infectious Diseases, Autoimmune Diseases, Metabolic Disorders, Cardiovascular Diseases, And Others), and geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of various chronic disease and the increasing awareness for biopharmaceuticals and personalized medicines

The global biopharmaceuticals market is estimated to grow at a CAGR of 7.98% during the forecast period from 2024 to 2030 to reach USD 713.61 billion by 2030. The demand for biopharmaceuticals is primarily being boosted by the growing burden of chronic, infectious, and neurological diseases and the growing geriatric population worldwide. In addition, increasing acceptance of biopharmaceuticals and personalized medicines, the ability of biopharmaceuticals to treat previously untreatable diseases, rising expenditure for research and development proficiencies, surging focus towards improving the condition of healthcare facilities, improving the overall healthcare infrastructure, increasing product launches and approvals, and innovation in product development among others, thereby contribute to the overall growth of the biopharmaceuticals market during the forecast period from 2024-2030.

Biopharmaceuticals Market Dynamics:

The increasing prevalence of chronic diseases such as cancers, neurological diseases, and others across the globe will increase the overall market of biopharmaceuticals. For instance, according to the Globocan Statistics 2020, in the year 2020, about 19.3 million people were suffering from cancer and more than 10 million people died from cancer, worldwide.

As per the Macmillan Cancer Support 2022, nearly 3 million people were living with cancer in the UK, rising to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040.

The increasing prevalence of cancers will increase the demand for biopharmaceuticals as protein-based biopharmaceuticals have significantly extended the lives of millions of cancer patients.

Growing investment in R&D capabilities, particularly in developed and developing nations, about medical equipment and technologies, will further generate profitable market expansion prospects. The medical instrument development process is augmenting the market growth rate through research and development proficiencies.

The biopharmaceutical products' capability to address previously untreatable conditions has paved the way for introducing innovative drugs in the market. For instance, in September 2022, Bluebird Bio, Inc.'s SKYSONA (elivaldogene autotemcel) slows the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD), was approved by CBER. Similarly, in June 2022, CBER approved PRIORIX, a live vaccine for measles, mumps, and rubella, manufactured by GSK plc.

Also, in February 2022, Johnson and Johnson and its China-focused partner company Legend Biotech Corp developed a therapy to treat white blood cell cancer type approved by the US Food and Drug Administration (FDA). New therapies that aid in treating oncologic disorders will add to the market growth over the forecast period.

Therefore, the above-mentioned factors will propel the biopharmaceuticals market during the forecast period from 2024-2030.

However, high-end manufacturing requirements, side effects related to biopharmaceuticals, and others may restrict the growth of the overall biopharmaceuticals market.

Biopharmaceuticals Market Segment Analysis:

Biopharmaceuticals Market by Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Protein, Recombinant Protein, Recombinant Hormones, Synthetic Immunomodulators, and Others), Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Diseases, Metabolic Disorders, Cardiovascular Diseases, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the biopharmaceuticals market, the monoclonal antibodies category is expected to amass a significant revenue share in the year 2023. This can be ascribed to the advantages and applications associated with the segment.

Monoclonal antibodies (MABs) are a type of immunotherapy. They work by triggering the immune system and helping it to attack cancer. The therapeutic applications of monoclonal antibodies include cancer, rheumatoid arthritis, multiple sclerosis, and cardiovascular diseases.

The usage of monoclonal antibodies in cancer therapy requires an understanding of the biological role of various antigens involved in tumor growth. Monoclonal antibody (mAb) allows a far more precise understanding of the humoral immune response by allowing dissection of this response into its B-lymphocyte populations. A large number of mAbs have been produced against renal, bladder, and prostate cancer antigens.

They can be used as therapeutic agents on their own or in combination with other treatments. Monoclonal antibodies have been successful in neutralizing pathogens, blocking cell receptors, modulating immune responses, and delivering therapeutic payloads, making them versatile tools for disease management.

The expansion of this market is mostly dependent on expanding research spending, growing clinical trials, and growing approvals. For instance, in July 2023, Transcenta Holding Limited received approval from the China Center for Drug Evaluation (CDE) to initiate a Phase II clinical trial of TST002(Blosozumab), a humanized anti-sclerostin monoclonal antibody. This study aims to evaluate the safety, tolerability, and pharmacokinetics of TST002 (Blosozumab) after single and multiple intravenous administrations in patients with reduced bone mineral density.

Also, in October 2022, PT217, a bispecific anti-Delta-like ligand 3 (DLL3)/anti-Cluster of Differentiation 47 (CD47) antibody, was developed by Phanes Therapeutics, Inc. It is a clinical-stage biotech company focused on oncology for patients with small cell lung cancer (SCLC) and other neuroendocrine cancers. It received Phase I clearance from the US Food and Drug Administration (FDA).

Therefore, owing to the above-mentioned factors, the monoclonal antibodies category is expected to register significant growth, thereby driving the growth of the overall biopharmaceuticals market during the forecast period.

North America is expected to dominate the overall Biopharmaceuticals Market:

Among all the regions, North America is estimated to account for the largest share of the biopharmaceuticals market in the year 2023. Owing to the significance of key growth factors such as the prevalence and incidence of chronic diseases, surging elderly population base, strong base of healthcare facilities, availability of advanced treatment options that specifically target the underlying causes of these complex diseases, providing improved therapeutic outcomes and enhanced patient, presence of key players, and increasing launches and approvals, and others, the market for biopharmaceuticals is expected to witness prosperity in the region during the forecast period 2022-2028.

The International Trade Administration (ITA) 2019, stated that the US is the largest market for biopharmaceuticals, accounting for one-third of the global market, and is the world leader in biopharmaceutical R&D. In 2019, more than 800,000 people worked in the biopharmaceutical industry in the United States across a broad range of occupations, including scientific research, technical support, and manufacturing. The US attracts the majority of global venture capital investments in start-up biopharmaceutical enterprises.

Additionally, the growing FDA approvals and new product launches for various indications will drive the segment. For instance, in February 2022, the US Food and Drug Administration issued an Emergency Use Authorization (EUA) for a new monoclonal antibody to treat COVID-19 that retains activity against the omicron variant. The EUA for bebtelovimab treats mild to moderate COVID-19 among adults and pediatric patients with a positive COVID-19 test who are at high risk for progression to severe COVID-19, including hospitalization or death. It is also for those for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.

Also, In May 2022, Eli Lilly and Company announced an investment of USD 2.1 billion to expand its manufacturing footprint in Indiana, United States.

Thus, the above-mentioned factors are likely to propel the growth of the biopharmaceuticals market in the region during the forecast period from 2024-2030.

Biopharmaceuticals Market Key Players:

Some of the key market players operating in the biopharmaceuticals market include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson, Novartis AG, Novo Nordisk AS, Pfizer Inc., GSK plc., F. Hoffmann-La Roche Ltd, Merck KGaA, Sanofi SA, AstraZeneca PLC, Bayer AG, Takeda Pharmaceutical Company Limited, UCB S.A., Boehringer Ingelheim International GmbH, DAIICHI SANKYO COMPANY, LIMITED, Biogen, Serum Institute of India, and others.

Recent Developmental Activities in the Biopharmaceuticals Market:

In March 2022, BioNTech SE reported the expansion of its strategic collaboration with Regeneron to advance the Company's FixVac candidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor, in advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate their combination in different patient populations with advanced NSCLC.

In January 2022, Amgen collaborated with Generate Biomedicines to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.

In May 2021, Amgen Inc. received FDA approval for Lumakras (sotorasib), a targeted therapy for non-small cell lung cancer (NSCLC) with specific genetic mutations.

Key Takeaways from the Biopharmaceuticals Market Report Study

Market size analysis for current biopharmaceuticals market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global biopharmaceuticals market.

Various opportunities available for the other competitors in the biopharmaceuticals market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current biopharmaceuticals market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for biopharmaceuticals market growth in the coming future?

Target Audience who can be benefited from this Biopharmaceuticals Market Report Study

Biopharmaceuticals product providers

Research organizations and consulting companies

Biopharmaceuticals-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in biopharmaceuticals

Various End-users who want to know more about the biopharmaceuticals market and the latest technological developments in the biopharmaceuticals market.

Frequently Asked Questions for the Biopharmaceuticals Market:

1. What are biopharmaceuticals?

Biopharmaceuticals, also known as biologic drugs or biologics, are medical products derived from biological sources such as living organisms, cells, or proteins.

2. What is the market for global biopharmaceuticals?

The global biopharmaceuticals market is estimated to grow at a CAGR of 7.98% during the forecast period from 2024 to 2030 to reach USD 713.61 billion by 2030.

3. What are the drivers for the global biopharmaceuticals market?

The demand for biopharmaceuticals is primarily being boosted by the increasing prevalence of chronic diseases, rising number of clinical trials, increasing surplus investments in biotech and pharma companies, growing awareness among the masses regarding the effectiveness and availability of biopharmaceuticals, increasing product launches and approvals, and others thereby contributing to the overall growth of the biopharmaceuticals market during the forecast period from 2024-2030.

4. Who are the key players operating in the global biopharmaceuticals market?

Some of the key market players operating in the biopharmaceuticals market include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson, Novartis AG, Novo Nordisk AS, Pfizer Inc., GSK plc., F. Hoffmann-La Roche Ltd, Merck KGaA, Sanofi SA, AstraZeneca PLC, Bayer AG, Takeda Pharmaceutical Company Limited, UCB S.A., Boehringer Ingelheim International GmbH, DAIICHI SANKYO COMPANY, LIMITED, Biogen, Serum Institute of India, and others.

5. Which region has the highest share in the biopharmaceuticals market?

North America is expected to dominate the overall biopharmaceuticals market during the forecast period from 2024-2030. Owing to factors such as the rising prevalence and incidence of chronic diseases, surging elderly population base, strong base of healthcare facilities, availability of advanced treatment options that specifically target the underlying causes of these complex diseases, providing improved therapeutic outcomes and enhanced patient, presence of key players, and increasing launches and approvals, among others the North America biopharmaceuticals market is expected to growth in coming years.

Table of Contents

1. Biopharmaceuticals Market Report Introduction

2. Biopharmaceuticals Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Biopharmaceuticals Market Key Factors Analysis

• 4.1. Biopharmaceuticals Market Drivers
  • 4.1.1. Increasing prevalence of chronic diseases
  • 4.1.2. Increasing acceptance of biopharmaceuticals and personalized medicines
  • 4.1.3. Ability of biopharmaceuticals to treat previously untreatable diseases
• 4.2. Biopharmaceuticals Market Restraints and Challenges
  • 4.2.1. High-end manufacturing requirements
  • 4.2.2. Side effects related to biopharmaceuticals
• 4.3. Biopharmaceuticals Market Opportunities
  • 4.3.1. Surging advancements in the arena of biotechnology

5. Biopharmaceuticals Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. Biopharmaceuticals Market Layout

• 6.1. By Product Type
  • 6.1.1. Monoclonal antibodies
  • 6.1.2. Recombinant Growth Factors
  • 6.1.3. Purified Protein
  • 6.1.4. Recombinant Protein
  • 6.1.5. Recombinant Hormones
  • 6.1.6. Synthetic Immunomodulators
  • 6.1.7. Others
• 6.2. By Application
  • 6.2.1. Oncology
  • 6.2.2. Inflammatory and Infectious Diseases
  • 6.2.3. Autoimmune Diseases
  • 6.2.4. Metabolic Disorders
  • 6.2.5. Cardiovascular diseases
  • 6.2.6. Others
• 6.3. By Geography
  • 6.3.1. North America Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.1.1. United States Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.1.2. Canada Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.1.3. Mexico Biopharmaceuticals Market Size in USD million (2021-2030)
  • 6.3.2. Europe Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.2.1. France Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.2.2. Germany Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.2.3. United Kingdom Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.2.4. Italy Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.2.5. Spain Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.2.6. Rest of Europe Biopharmaceuticals Market Size in USD million (2021-2030)
  • 6.3.3. Asia-Pacific Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.3.1. China Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.3.2. Japan Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.3.3. India Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.3.4. Australia Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.3.5. South Korea Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.3.6. Rest of Asia-Pacific Biopharmaceuticals Market Size in USD million (2021-2030)
  • 6.3.4. Rest of the World (RoW) Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.4.1. Middle East Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.4.2. Africa Biopharmaceuticals Market Size in USD million (2021-2030)
    • 6.3.4.3. South America Biopharmaceuticals Market Size in USD million (2021-2030)

7. Biopharmaceuticals Market Company and Product Profiles

• 7.1. AbbVie Inc.
  • 7.1.1. Company Overview
  • 7.1.2. Company Snapshot
  • 7.1.3. Financial Overview
  • 7.1.4. Product Listing
  • 7.1.5. Entropy
• 7.2. Amgen Inc.
  • 7.2.1. Company Overview
  • 7.2.2. Company Snapshot
  • 7.2.3. Financial Overview
  • 7.2.4. Product Listing
  • 7.2.5. Entropy
• 7.3. Bristol-Myers Squibb Company
  • 7.3.1. Company Overview
  • 7.3.2. Company Snapshot
  • 7.3.3. Financial Overview
  • 7.3.4. Product Listing
  • 7.3.5. Entropy
• 7.4. Eli Lilly and Company
  • 7.4.1. Company Overview
  • 7.4.2. Company Snapshot
  • 7.4.3. Financial Overview
  • 7.4.4. Product Listing
  • 7.4.5. Entropy
• 7.5. Johnson & Johnson
  • 7.5.1. Company Overview
  • 7.5.2. Company Snapshot
  • 7.5.3. Financial Overview
  • 7.5.4. Product Listing
  • 7.5.5. Entropy
• 7.6. Novartis AG
  • 7.6.1. Company Overview
  • 7.6.2. Company Snapshot
  • 7.6.3. Financial Overview
  • 7.6.4. Product Listing
  • 7.6.5. Entropy
• 7.7. Novo Nordisk AS
  • 7.7.1. Company Overview
  • 7.7.2. Company Snapshot
  • 7.7.3. Financial Overview
  • 7.7.4. Product Listing
  • 7.7.5. Entropy
• 7.8. Pfizer Inc.
  • 7.8.1. Company Overview
  • 7.8.2. Company Snapshot
  • 7.8.3. Financial Overview
  • 7.8.4. Product Listing
  • 7.8.5. Entropy
• 7.9. GSK plc.
  • 7.9.1. Company Overview
  • 7.9.2. Company Snapshot
  • 7.9.3. Financial Overview
  • 7.9.4. Product Listing
  • 7.9.5. Entropy
• 7.10. F. Hoffmann-La Roche Ltd
  • 7.10.1. Company Overview
  • 7.10.2. Company Snapshot
  • 7.10.3. Financial Overview
  • 7.10.4. Product Listing
  • 7.10.5. Entropy
• 7.11. Merck KGaA
  • 7.11.1. Company Overview
  • 7.11.2. Company Snapshot
  • 7.11.3. Financial Overview
  • 7.11.4. Product Listing
  • 7.11.5. Entropy
• 7.12. Sanofi SA
  • 7.12.1. Company Overview
  • 7.12.2. Company Snapshot
  • 7.12.3. Financial Overview
  • 7.12.4. Product Listing
  • 7.12.5. Entropy
• 7.13. AstraZeneca PLC
  • 7.13.1. Company Overview
  • 7.13.2. Company Snapshot
  • 7.13.3. Financial Overview
  • 7.13.4. Product Listing
  • 7.13.5. Entropy
• 7.14. Bayer AG
  • 7.14.1. Company Overview
  • 7.14.2. Company Snapshot
  • 7.14.3. Financial Overview
  • 7.14.4. Product Listing
  • 7.14.5. Entropy
• 7.15. Takeda Pharmaceutical Company Limited.
  • 7.15.1. Company Overview
  • 7.15.2. Company Snapshot
  • 7.15.3. Financial Overview
  • 7.15.4. Product Listing
  • 7.15.5. Entropy
• 7.16. UCB S.A.
  • 7.16.1. Company Overview
  • 7.16.2. Company Snapshot
  • 7.16.3. Financial Overview
  • 7.16.4. Product Listing
  • 7.16.5. Entropy
• 7.17. Boehringer Ingelheim International GmbH
  • 7.17.1. Company Overview
  • 7.17.2. Company Snapshot
  • 7.17.3. Financial Overview
  • 7.17.4. Product Listing
  • 7.17.5. Entropy
• 7.18. DAIICHI SANKYO COMPANY, LIMITED
  • 7.18.1. Company Overview
  • 7.18.2. Company Snapshot
  • 7.18.3. Financial Overview
  • 7.18.4. Product Listing
  • 7.18.5. Entropy
• 7.19. Biogen
  • 7.19.1. Company Overview
  • 7.19.2. Company Snapshot
  • 7.19.3. Financial Overview
  • 7.19.4. Product Listing
  • 7.19.5. Entropy
• 7.20. Serum Institute of India
  • 7.20.1. Company Overview
  • 7.20.2. Company Snapshot
  • 7.20.3. Financial Overview
  • 7.20.4. Product Listing
  • 7.20.5. Entropy

8. KOL Views

9. Project Approach

10. DelveInsight Capabilities

11. About DelveInsight

12. Disclaimer & Contact Us